The Latest Breaking News on Pharma

Record-high inflation, the Federal Reserve's hawkish stance, and growing recession fears have increased market volatility. Nevertheless, despite the unsettling macroenvironment, few stocks have delivered stable returns and could continue to beat the market based on their solid growth attributes. AbbVie Inc. (ABBV), J. Jill Inc. (JILL), and Bassett Furniture Industries…

The new chief at the Food and Drug Administration's tobacco center has inherited a raft of problems

As demand for menopause drugs soars, we trace the oestrogen production line from Chinese soya bean fields to European pharmacy shelves

The application for children ages 6 months to under 6 years is expected to be completed later this year.

As billions of dollars in opioid lawsuit settlements are starting to flow to governments, families and advocates impacted by the opioid crisis are pushing for a meaningful say in how the money will be used

Biotech stock Timber Pharmaceuticals (TMBR) is down more than 70% year-to-date. Analysts expect it to keep reporting losses over the next two years. So, will it be wise to buy the stock now? Read on to learn our view….

The number of suspected drug deaths in Scotland in the first six months of this year has dropped by 22 compared to last year.

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should drive its growth in the coming quarters. Given GILD’s discounted valuation, we think it could be wise to buy this…